Faster steroid-free remission with tocilizumab compared to methotrexate in giant cell arteritis: a real-life experience in two reference centres
Internal and Emergency Medicine · 2024
DOI: 10.1007/s11739-024-03722-4 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Internal and Emergency Medicine, 2024. Verfasst von Luca Quartuccio und 7 weiteren Autor:innen. Beteiligte Einrichtung: Rheumatology Division, Department of Medicine (DMED), University of Udine, Udine, Italy. luca.quartuccio@uniud.it. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Giant Cell Arteritis, Methotrexate. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Udine.
Abstract (Originalsprache)
Glucocorticoids (GCs) are still the mainstay of treatment of giant cell arteritis (GCA). Although GCs are highly effective in GCA, the high burden of toxicity of GCs as well as the disease relapse during GC tapering is well documented. To compare the efficacy and rapidity of TCZ and MTX as steroid-sparing agents in a real-life cohort of GCA patients. A retrospective analysis was conducted including patients with newly diagnosed GCA from the Rheumatology Units of Udine and Rome. The inclusion criterion was the treatment with TCZ or MTX as first steroid-sparing drug. 112 GCA patients (81 females) with a median age of 70 (IQ 65–75) years were collected. Thirty-one out of 112 (27.7%) patients were treated with TCZ (162 mg/week), while 81/112 (72.3%) patients received MTX (up to 20 mg/week) as a GC-sparing agent. At month 6 after GCA onset, 5/31 (16.1%) patients in TCZ group and none in MTX group were in GC-free sustained remission ( p value = 0.001). Similarly, at month 12, 64.5% (20/31) and 11.1% (9/81) of patients were in sustained GC-free remission in TCZ and MTX group, respectively ( p value
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Rheumatology Division, Department of Medicine (DMED), University of Udine, Udine, Italy. luca.quartuccio@uniud.it.
- Rheumatology Division, Department of Medicine (DMED), University of Udine, Udine, Italy.
- Institute of Statistics, Department of Medicine (DMED), University of Udine, Udine, Italy.
- Division of Rheumatology, Institute of Rheumatology and Affine Sciences, School of Medicine, Catholic University of the Sacred Heart, Rome, Italy.
ORCID-Profile: Luca Quartuccio
Förderung
- Università degli Studi di Udine
Zitieren
APA
Quartuccio, L., Treppo, E., De Martino, M., Pillon, M., Perniola, S., Bruno, D., Isola, M., & Gremese, E. (2024). Faster steroid-free remission with tocilizumab compared to methotrexate in giant cell arteritis: a real-life experience in two reference centres. Internal and Emergency Medicine. https://doi.org/10.1007/s11739-024-03722-4
Vancouver
Quartuccio L, Treppo E, De Martino M, Pillon M, Perniola S, Bruno D, et al. Faster steroid-free remission with tocilizumab compared to methotrexate in giant cell arteritis: a real-life experience in two reference centres. Internal and Emergency Medicine. 2024. doi:10.1007/s11739-024-03722-4
BibTeX
@article{Quartuccio2024,
author = {Quartuccio, Luca and Treppo, Elena and De Martino, Maria and Pillon, Maria and Perniola, Simone and Bruno, Dario and Isola, Miriam and Gremese, Elisa},
title = {Faster steroid-free remission with tocilizumab compared to methotrexate in giant cell arteritis: a real-life experience in two reference centres},
journal = {Internal and Emergency Medicine},
year = {2024},
doi = {10.1007/s11739-024-03722-4}
}
EUVIMED